ReviewTrends in pharmacological sciences2019
Predicting and Understanding the Human Microbiome's Impact on Pharmacology.
Review in Trends in pharmacological sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Associations of oral microbiome diversity with prevalent cancer: a population-based cross-sectional study.Archives of microbiology · 2026Article
- Pharmacomicrobiomics.Clinical pharmacology and therapeutics · 2025Review
- Resveratrol inhibits African swine fever virus replicationEmerging microbes & infections · 2025Article
- Rinderine suppresses African swine fever virus replication in porcine alveolar macrophages by dual targeting of membrane-associated profilin 1 and phosphatidylethanolamine.Emerging microbes & infections · 2025Article
- Microbial Crosstalk with Therapy: Pharmacomicrobiomics in AML-One Step Closer to Personalized Medicine.Biomedicines · 2025Review
- Review
- Microbiome Dynamics: A Paradigm Shift in Combatting Infectious Diseases.Journal of personalized medicine · 2024Review
- Exploring the influence of the microbiome on the pharmacology of anti-asthmatic drugs.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Human Gut Microbiota and Drug Metabolism.Microbial ecology · 2023Review
- Interactions Between Antidepressants and Intestinal Microbiota.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023Article
- The gut microbiome-Does stool represent right?Heliyon · 2023Article
- Beneficial insights into postbiotics against colorectal cancer.Frontiers in nutrition · 2023Review
- Pharmacomicrobiomics in Anticancer Therapies: Why the Gut Microbiota Should Be Pointed Out.Genes · 2022Review
- Multi-compound and drug-combination pharmacokinetic research on Chinese herbal medicines.Acta pharmacologica Sinica · 2022Review
- Probiotics: Protecting Our Health from the Gut.Microorganisms · 2022Review
- UGT1A1 and UGT1A9 Are Responsible for Phase II Metabolism of Tectorigenin and Irigenin In Vitro.Molecules (Basel, Switzerland) · 2022Article
- Involvement of Abnormal Gut Microbiota Composition and Function in Doxorubicin-Induced Cardiotoxicity.Frontiers in cellular and infection microbiology · 2022Article
- Machine Learning Predicts Drug Metabolism and Bioaccumulation by Intestinal Microbiota.Pharmaceutics · 2021Article
- The Role of Gut Microbiota in Hypertension Pathogenesis and the Efficacy of Antihypertensive Drugs.Current hypertension reports · 2021Review
- Emulating the gut-liver axis: Dissecting the microbiome's effect on drug metabolism using multiorgan-on-chip models.Current opinion in endocrine and metabolic research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Our bodies each possess a unique and dynamic collection of microbes and viruses, collectively the 'microbiome', with distinct metabolic capacities from our human cells. Unforeseen modification of drugs by the microbiome can drastically alter their clinical effectiveness, with the most dramatic cases leading to fatal drug interactions. Pharmaceuticals can be activated, deactivated, toxified, or release metabolites that alter the 'canonical' pharmacokinetics of the drug. Thus, predicting and characterizing microbe-drug interactions is necessary to develop and implement personalized drug administration protocols and, more broadly, to improve drug safety and efficacy. In this review, we focus on microbiome-driven alterations to drug pharmacokinetics and provide a research framework for pharmacologists interested in characterizing microbiome interactions with any drug of interest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.